מנבאו

Država: Izrael

Jezik: hebrejski

Izvor: Ministry of Health

Aktivni sastojci:

MENINGOCOCCAL VACCINES GROUP A; MENINGOCOCCAL VACCINES GROUP C; MENINGOCOCCAL VACCINES GROUP W; MENINGOCOCCAL VACCINES GROUP Y

Dostupno od:

GLAXO SMITH KLINE (ISRAEL) LTD

ATC koda:

J07AH02

Farmaceutski oblik:

POWDER AND SOLVENT FOR SOLUTION FOR INJECTION

Sastav:

MENINGOCOCCAL VACCINES GROUP Y 5 MCG / 0.5 ML; MENINGOCOCCAL VACCINES GROUP W 5 MCG / 0.5 ML; MENINGOCOCCAL VACCINES GROUP C 5 MCG / 0.5 ML; MENINGOCOCCAL VACCINES GROUP A 10 MCG / 0.5 ML

Administracija rute:

תוך-שרירי

Tip recepta:

מרשם נדרש

Proizveden od:

GLAXO SMITHKLINE VACCINES S.R.L., ITALY

Terapijska grupa:

OTHER MENINGOCOCCAL MONOVALENT PURIFIED POLYSACCHARIDES ANTIGEN

Područje terapije:

OTHER MENINGOCOCCAL MONOVALENT PURIFIED POLYSACCHARIDES ANTIGEN

Terapijske indikacije:

Menveo is indicated for active immunization of children (2 years of age and above), adolescents and adults up to the age of 55 years, at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease. The use of this vaccine should be in accordance with official recommendations.

Proizvod sažetak:

החיסון יינתן עבור חולה הלוקה באחד מאלה:1. אספלניה, היפוספלניה אנטומית או תפקודית, נרכשת או מולדת.2. חסר במערכת המשלים כגון חסר בפקטור D, פרופרידין ובמרכיב המשלים C5-9 או C3

Datum autorizacije:

2017-08-31